Zhao 2006.

Methods	Randomised clinical trial with 2 arms: three dimensional conformal radiotherapy (3‐DCRT) plus transarterial chemoembolisation (TACE) versus TACE
Participants	96 people with inoperable primary liver cancer. TACE + 3‐DCRT = 49; TACE = 47 Median age: 52 years Male/female: 59/37 Recruitment: January 1998 to April 2000 Diagnostic criteria: KPS ≥ 70 Normal liver function No TACE or RT contraindicated Early stage of liver portal area of the liver cancer Not suitable for surgery, such as liver cancer merger of liver cirrhosis Voluntary choice of TACE and/or 3‐DCRT No portal vein tumour thrombus No distant metastases No ascites Gross tumour volume ＜ 6 cm 79 participants had pathologic diagnosis; others were diagnosed by clinical symptoms, imaging, and alpha‐fetoprotein.
Interventions	Planning scan by spiral computed tomography, design CTV, and PTV. The machine is 2100C linear accelerator. 3‐DCRT: 45 to 55 Gy; treatment is administered every other day
Outcomes	alpha‐fetoprotein Short‐term effects Survival rate Toxic and adverse effects
Notes	Country of the study: China We contacted the corresponding author on 19 March 2016 to provide missing data, but have not yet received any feedback. Funding: unclear
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The study is described as a randomised clinical trial, but the method of randomisation is not mentioned.
Allocation concealment (selection bias)	Unclear risk	The method used to conceal the allocation was not described.
Blinding of participants and personnel (performance bias) All outcomes	High risk	The trial was not blinded, so that the allocation was known during the trial.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Outcome assessment was not blinded.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	There were insufficient data to assess attrition bias.
Selective reporting (reporting bias)	High risk	The study did not report cancer‐related mortality, quality of life, or serious adverse events.
For profit bias	Unclear risk	Unclear funding source
Other bias	Unclear risk	Unclear risk of other bias

Epi‐ADM: doxorubicin and epirubicin; cGy: centigray; CTV: clinical target volume; DDP: cisplatin; Gy: gray; KPS: Karnofsky performance score; PTV: planning target volume; THP: tetrahydropalmatine; TLC: total leukocytic count; TNM: tumour, node and metastasis.